Proposal for a regulation on health technology assessment in Europe - opinions of policy makers, payers and academics from the field of HTA.


Journal

Expert review of pharmacoeconomics & outcomes research
ISSN: 1744-8379
Titre abrégé: Expert Rev Pharmacoecon Outcomes Res
Pays: England
ID NLM: 101132257

Informations de publication

Date de publication:
Jun 2019
Historique:
pubmed: 31 1 2019
medline: 3 5 2019
entrez: 31 1 2019
Statut: ppublish

Résumé

In January 2018 the European Commission published a Proposal for a Regulation on Health Technology Assessment (HTA): 'Proposal for a Regulation on health technology assessment and amending Directive 2011/24/EU'. A number of stakeholders, including some Member States, welcomed this initiative as it was considered to improve collaboration, reduce duplication and improve efficiency. There were however a number of concerns including its legal basis, the establishment of a single managing authority, the preservation of national jurisdiction over HTA decision-making and the voluntary/mandatory uptake of joint assessments by Member States. Areas covered: This paper presents the consolidated views and considerations on the original Proposal as set by the European Commission of a number of policy makers, payers, experts from pricing and reimbursement authorities and academics from across Europe. Expert commentary: The Proposal has since been extensively discussed at Council and while good progress has been achieved, there are still divergent positions. The European Parliament gave a number of recommendations for amendments. If the Proposal is approved, it is important that a balanced, improved outcome is achieved for all stakeholders. If not approved, the extensive contribution and progress attained should be sustained and preserved, and the best alternative solutions found.

Identifiants

pubmed: 30696372
doi: 10.1080/14737167.2019.1575730
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

251-261

Commentaires et corrections

Type : CommentIn

Auteurs

Patricia Vella Bonanno (P)

a Strathclyde Institute of Pharmacy and Biomedical Sciences , University of Strathclyde , Glasgow , UK.

Anna Bucsics (A)

b Mechanism of Coordinated Access to Orphan Medicinal Products (MoCA) , Brussels , Belgium.

Steven Simoens (S)

c KU Leuven Department of Pharmaceutical and Pharmacological Sciences , Leuven , Belgium.

Antony P Martin (AP)

d Health Economics Centre , University of Liverpool Management School , Liverpool , UK.

Wija Oortwijn (W)

e Department for Health Evidence , Radboud University Medical Center , Nijmegen , The Netherlands.

Jolanta Gulbinovič (J)

f Department of Pathology, Forensic Medicine and Pharmacology , Institute of Biomedical Sciences, Faculty of Medicine, VilniusUniversity , Vilnius , Lithuania.

Celia Rothe (C)

g Department of Drug Management, Faculty of Health Sciences , Jagiellonian University Medical College , Krakow , Poland.

Angela Timoney (A)

a Strathclyde Institute of Pharmacy and Biomedical Sciences , University of Strathclyde , Glasgow , UK.
h NHS Lothian , Edinburgh , UK.

Alessandra Ferrario (A)

i Division of Health Policy and Insurance Research, Department of Population Medicine , Harvard Medical School and Harvard Pilgrim Health Care Institute , Boston , MA , USA.

Mohamed Gad (M)

j Global Health and Development Group , Imperial College , London , UK.

Ahmed Salem (A)

k IQVIA , Brussels , Belgium.

Iris Hoxha (I)

l Department of Pharmacy, Faculty of Medicine , University of Medicine , Tirana , Albania.

Robert Sauermann (R)

m Hauptverband der ÖsterreichischenSozialversicherungsträger , Vienna , Austria.

Maria Kamusheva (M)

n Department of Organization and Economics of Pharmacy, Faculty of Pharmacy , Medical University-Sofia , Bulgaria.

Maria Dimitrova (M)

n Department of Organization and Economics of Pharmacy, Faculty of Pharmacy , Medical University-Sofia , Bulgaria.

Guenka Petrova (G)

n Department of Organization and Economics of Pharmacy, Faculty of Pharmacy , Medical University-Sofia , Bulgaria.

Ott Laius (O)

o State Agency of Medicines , Tartu , Estonia.

Gisbert Selke (G)

p Wissenschaftliches Institut der AOK (WidO) , Berlin , Germany.

Vasilios Kourafalos (V)

q EOPYY-National Organization for the Provision of Healthcare Services , Athens , Greece.

John Yfantopoulos (J)

r School of Economics and Political Science , University of Athens , Athens , Greece.

Einar Magnusson (E)

s Department of Health Services , Ministry of Health , Reykjavík , Iceland.

Roberta Joppi (R)

t Pharmaceutical Drug Department , Azienda Sanitaria Locale of Verona , Verona , Italy.

Arianit Jakupi (A)

u UBT - Higher Education Institute , Prishtina , Kosovo.

Tomasz Bochenek (T)

g Department of Drug Management, Faculty of Health Sciences , Jagiellonian University Medical College , Krakow , Poland.

Magdalene Wladysiuk (M)

v HTA Consulting , Cracow , Poland.

Claudia Furtado (C)

w Pharmaceutical Division , INFAMED , Lisbon , Portugal.

Vanda Marković-Peković (V)

x Ministry of Health and Social Welfare , Banja Luka , Republic of Srpska, Bosnia and Herzegovina.
y Department of Social Pharmacy , University of Banja Luka, Faculty of Medicine , Banja Luka , Republic of Srpska, Bosnia and Herzegovina.

Ileana Mardare (I)

z Faculty of Medicine, Public Health and Management Department , "Carol Davila" University of Medicine and Pharmacy Bucharest , Bucharest , Romania.

Dmitry Meshkov (D)

aa National Research Institution for Public Health , Moscow , Russia.

Jurij Fürst (J)

ab Health Insurance Institute , Ljubljana , Slovenia.

Dominik Tomek (D)

ac Faculty of Medicine, Slovak Medical University , Bratislava , Slovakia .

Merce Obach Cortadellas (MO)

ad Drug Territorial Action Unit , Catalan Health Service , Barcelona , Spain.

Corrine Zara (C)

ad Drug Territorial Action Unit , Catalan Health Service , Barcelona , Spain.

Alan Haycox (A)

d Health Economics Centre , University of Liverpool Management School , Liverpool , UK.

Stephen Campbell (S)

ae Centre for Primary Care, Division of Population Health, Health Services Research and Primary Care , University of Manchester , Manchester , UK.
af NIHR Greater Manchester Patient Safety Translational Research Centre, School of Health Sciences , University of Manchester , Manchester , UK.

Brian Godman (B)

a Strathclyde Institute of Pharmacy and Biomedical Sciences , University of Strathclyde , Glasgow , UK.
d Health Economics Centre , University of Liverpool Management School , Liverpool , UK.
ag Division of Clinical Pharmacology , Karolinska, Karolinska Institutet , Stockholm , Sweden.
ah Department of Public Health Pharmacy and Management, School of Pharmacy , Sefako Makgatho Health Sciences University , Garankuwa , South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH